Longitudinal changes in electrophysiological findings caused by nusinersen administration in patients with spinal muscular atrophy type 2 or type 3

被引：0
|
作者：
Arahata, Y. [1 ]
Ishiyama, A. [1 ]
Takeshita, E. [1 ]
Shimizu-Motohashi, Y. [1 ]
Komaki, H. [1 ]
Sasaki, M. [1 ]
机构：
[1] Natl Ctr Hosp, NCNP, Tokyo, Japan
来源：
NEUROMUSCULAR DISORDERS | 2019年 / 29卷
关键词：
D O I：
10.1016/j.nmd.2019.06.535
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.373
引用
收藏
页码：S190 / S190
页数：1
相关论文
共 50 条
  • [21] Nusinersen treatment and cerebrospinal fluid neurofilaments: An explorative study on Spinal Muscular Atrophy type 3 patients
    Faravelli, Irene
    Meneri, Megi
    Saccomanno, Domenica
    Velardo, Daniele
    Abati, Elena
    Gagliardi, Delia
    Parente, Valeria
    Petrozzi, Lucia
    Ronchi, Dario
    Stocchetti, Nino
    Calderini, Edoardo
    D'Angelo, Grazia
    Chidini, Giovanna
    Prandi, Edi
    Ricci, Giulia
    Siciliano, Gabriele
    Bresolin, Nereo
    Comi, Giacomo Pietro
    Corti, Stefania
    Magri, Francesca
    Govoni, Alessandra
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2020, 24 (05) : 3034 - 3039
  • [22] Muscle MRI findings in spinal muscular atrophy type 3
    Karasoy, H.
    Ozkan, T.
    Argin, M.
    Yuceyar, A.
    Ekmekci, O.
    NEUROMUSCULAR DISORDERS, 2017, 27 : S122 - S122
  • [23] Nonrespiratory complications of nusinersen-treated spinal muscular atrophy type 1 patients
    Lavie, Moran
    Rochman, Mika
    Sagi, Liora
    Feler, Anat Yerushalmy
    Ovadia, Dror
    Cahal, Michal
    Be'er, Moria
    Sadot, Efraim
    Fattal-Valevski, Aviva
    Amirav, Israel
    PEDIATRIC PULMONOLOGY, 2022, 57 (03) : 686 - 694
  • [24] Nusinersen treatment in a type 3 spinal muscular atrophy patient during early pregnancy
    Schon, Miguel
    Domingues, Sara
    de Carvalho, Mamede
    Oliveira Santos, Miguel
    NEUROLOGICAL SCIENCES, 2023, 44 (5) : 1803 - 1804
  • [25] Clinical and Electropthysiological outcomes of Spinal Muscular Atrophy type 1 patients treated with Nusinersen
    Kern-Smith, Emily
    Verma, Sumit
    NEUROLOGY, 2019, 92 (15)
  • [26] Clinical outcomes in patients with spinal muscular atrophy type 1, 2 or 3 after 1 year of nusinersen therapy
    Waldrop, M.
    Lowes, L.
    Toops, J.
    Alfano, L.
    Miller, N.
    Iammarino, M.
    Kotha, K.
    Paul, G.
    Moore-Clingenpeel, M.
    Tsao, C.
    Noritz, G.
    Shell, R.
    Flanigan, K.
    NEUROMUSCULAR DISORDERS, 2019, 29 : S188 - S188
  • [27] Long-term CSF responses in adult patients with spinal muscular atrophy type 2 or 3 on treatment with nusinersen
    Cebulla, Gina
    Hai, Ling
    Warnken, Uwe
    Guengoer, Cansu
    Hoffmann, Dirk C.
    Korporal-Kuhnke, Mirjam
    Wildemann, Brigitte
    Wick, Wolfgang
    Kessler, Tobias
    Weiler, Markus
    JOURNAL OF NEUROLOGY, 2025, 272 (04)
  • [28] Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: Real world data from Hungarian patients
    Szabo, Lena
    Gergely, Anita
    Jakus, Rita
    Fogarasi, Andras
    Grosz, Zoltan
    Molnar, Maria Judit
    Andor, Ildiko
    Schulcz, Orsolya
    Goschler, Adam
    Medveczky, Erika
    Czovek, Dorottya
    Herczegfalvi, Agnes
    EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2020, 27 : 37 - 42
  • [29] Effect of Aggressive Therapies on Spinal Muscular Atrophy Type 1 Patients Receiving Nusinersen
    Tiongson, Emmanuelle
    Cowell, Melissa
    Kitabjian, Anna
    Gillett, Emily
    Lew, Cheryl
    Ramos-Platt, Leigh
    NEUROLOGY, 2019, 92 (15)
  • [30] Nusinersen for Type 1 Spinal Muscular Atrophy: A Father's Perspective
    Hoot, Nathan R.
    PEDIATRICS, 2019, 144 (04)
12345